ESMO Congress 2026

Iza-bren PANKU-Lung01 Hits PFS Primary Endpoint in EGFR-TKI-Resistant NSCLC; Su Chunxia Discusses Later-Line Positioning

The Phase III PANKU-Lung01 trial of iza-bren (BL-B01D1) met its primary PFS endpoint in advanced NSCLC resistant to EGFR-TKIs and was selected as an LBA at the 2026 ESMO Congress, with data due on the 26th. Historical platinum-based doublet chemotherapy achieved an ORR of about 30% and median PFS of 4 to 5 months, while the cited Phase II monotherapy data for iza-bren showed an ORR of 66.0% and median PFS of 12.5 months.

ESMO 2026: BXP-001 Plus Radiotherapy Significantly Extends Progression-Free Survival in iNATURE Advanced Tumor Randomized Trial

The iNATURE trial, presented at ESMO 2026, showed that BXP-001 combined with radiotherapy significantly extended progression-free survival in a randomized controlled study of advanced tumors. The trial was co-sponsored by Genvoy Bio/Bay Bio and the University of Hong Kong-Shenzhen Hospital, with the phase 2/3 results presented as rapid oral and poster presentations in Madrid, Spain on October 24, 2026. The original report also claims notable efficacy in post-surgical recurrence prevention, but lists no specific PFS figures, sample size, or hazard ratio.

ESMO 2026 HCC Updates: C-CAR031 and BGB-B2033 Show Preliminary Efficacy, LEAP-012 Long-Term Analysis Shows No OS Benefit

ESMO 2026 published abstracts from three advanced HCC studies. Phase I updates for C-CAR031 and BGB-B2033 showed preliminary antitumor activity, while the long-term LEAP-012 analysis showed no OS benefit. C-CAR031 achieved an ORR of 44% and DCR of 92% in 36 patients, with tumor lysis syndrome-related deaths and interstitial lung disease reported; confirmed ORR across BGB-B2033 dose groups in 110 patients ranged from 16.0% to 35.7%, and 450 mg was selected as the recommended phase II dose.

OptiTROP-Lung04 Final OS Analysis to Report at ESMO 2026 in EGFR-TKI-Resistant NSCLC

Experts review survival data for sacituzumab tirumotecan in EGFR-TKI-resistant NSCLC. The final overall survival analysis of OptiTROP-Lung04 will be presented at ESMO 2026.

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

Henlius Serplulimab ASTRIDE US Bridging Data to Be Presented Orally at ESMO 2026

Henlius released the ASTRIDE abstract at ESMO 2026. The US head-to-head bridging study will be presented as an oral report on serplulimab versus atezolizumab, both with chemotherapy, as first-line treatment for ES-SCLC. At a median follow-up of 14.1 months, median OS was 12.4 months with serplulimab versus 10.2 months with atezolizumab; 24-month OS rates were 32.2% and 17.6%. Safety was generally comparable between groups with no new safety signals; HANSIZHUANG had 10 studies accepted at the congress.

ESMO 2026: Qilu's QL1706 Posts 30.95-Month OS in Phase 3 First-Line Cervical Cancer

At ESMO 2026, Qilu Pharmaceutical reported phase 3 overall survival of 30.95 months for QL1706, a PD-1/CTLA-4 bispecific antibody, plus chemotherapy with or without bevacizumab as first-line treatment of persistent, recurrent or metastatic cervical cancer.

The Convergence: What All of This Has Been Moving Toward

ESMO 2026 Presents Six Mirvetuximab Soravtansine Studies Spanning Platinum-Resistant First-Line, Platinum-Sensitive Combinations and Chinese Real-World Data

The 2026 ESMO congress includes six mirvetuximab soravtansine (MIRV) abstracts, covering a post hoc analysis of first-line therapy and responders in FRα-positive platinum-resistant ovarian cancer, long-term follow-up from Chinese real-world data, pretreatment albumin as a predictor, the FLORENZA combination regimen, and hematologic safety of carboplatin combination in platinum-sensitive ovarian cancer.

Updated cancer treatment framework offers new guidance on actionability and resistance biomarkers

ESMO has published ESCAT v2 in Annals of Oncology (DOI: 10.1016/j.annonc.2026.09.008), with A. El Helali as first author.

ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win - Fierce Biotech

ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after ‘great result’ in early-stage test - Fierce Biotech

ESMO 2026 - Fierce Biotech

ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up - Fierce Biotech

At ESMO, GSK's head of oncology R&D said the mo-rez data reinforce confidence in the ADC as phase 3 development accelerates.

ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2

Chia Tai Tianqing Reports Phase III Results for TQB2102 in HER2-Low Breast Cancer at ESMO

Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical, reported pivotal Phase III results for its independently developed TQB2102 in HER2-low breast cancer, selected as a late-breaking abstract for a proffered paper session at ESMO. The abstract showed a median progression-free survival of 16.4 months with TQB2102 versus 5.5 months with comparator chemotherapy, an approximately 71% reduction in risk of disease progression or death, and a 2.2% incidence of treatment-related ILD.

ESMO 2026: Professor Huang Jun Interprets the CRIT Precision-Targeted Neoadjuvant Study in Locally Advanced Rectal Cancer

At ESMO 2026, Professor Huang Jun presented the CRIT phase 2 study, in which 49 patients with high-risk pMMR/MSS locally advanced rectal cancer achieved an overall pathological complete response (pCR) rate of 51.1%. Treatment was selected by RAS/BRAF status, using cetuximab beta or bevacizumab; pCR rates were 57.1% in the wild-type subgroup and 46.2% in the mutant subgroup. Of 47 patients who underwent surgery, 24 achieved pCR, and the R0 resection rate was 100%.

ESMO 2026 Chinese Orals: Dual TKI Improves MET-Amplified Resistance, CS2009 and Ivonescimab Report NSCLC and Thymic Carcinoma Data

Three Chinese-led oral presentations at ESMO 2026 updated data on MET-amplification resistance, NSCLC, and thymic carcinoma. A dual-TKI regimen significantly improved PFS in a randomized phase 3 study: NCT06110663 randomized 314 patients, with IRC-assessed mPFS of 6.2 vs 4.4 months, HR 0.601, P<0.001. CS2009 showed a preliminary ORR/DCR of 81.3%/100% in the evaluable first-line PD-L1 TPS≥50% population.

2026 ESMO Preview: Pimicotinib MANEUVER 2-Year TGCT Follow-Up and Three Nirogacestat Desmoid Tumor Datasets

Five studies from Merck KGaA's pimicotinib and nirogacestat were accepted for the 2026 ESMO congress, covering long-term follow-up and quality of life in TGCT, as well as dose-reduction, real-world, and indirect comparison evidence in desmoid tumors.

Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners

Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer